TO THE EDITOR
Waldenströ m's macroglobulinemia (WM) is a generalized chronic lymphoproliferative disorder characterized by the production of a monoclonal immunoglobulin M (IgM) by well-differentiated plasmacytic lymphocytes. 1 The standard therapy of WM is based on alkylating agents, with or without glucocorticoids. These treatments induce a response in about half of previously untreated patients, with a median survival time of approximately 5 years. 2, 3 Few reports are available on the treatment of patients who develop primary or secondary resistance to first-line therapies. In this context, our group demonstrated that fludarabine induced a 30% objective response rate despite intensive previous treatment in most cases. The overall median survival time and the time to treatment failure were 23 months and 32 months, respectively. 4 To date, the issue of how to treat patients relapsing after fludarabine has not been adequately addressed. We reported a clinical observation of retreatment by fludarabine at the relapse time.
A 37-year-old man was diagnosed with WM following investigation of anemia in July 1994. He was anemic with adenopathy and hepatosplenomegaly involvement, IgM was 73 g/l. He received three courses of CVP regimen and attained a PR with infectious complication. Then, chlorambucil therapy was given at 6 mg per day for 18 months with a plateau level of IgM at 20 g/l. Eighty months after the begining of chlorambucil, IgM raised to 36 g/l without adenopathy or spleen involvement. He began fludarabine infusion at the dose of 25 mg/m 2 /day × 5 days, every 4 weeks, associated with acyclovir and pentacarinate to prevent opportunistic infection. Prior to beginning fludarabine his absolute CD4
+ and CD8 + lymphocyte counts were 190/l and 475/l, respectively. After six cycles, a PR was noted on IgM decreased to 12 g/l and bone marrow had only minimal lymphoplasmocytoid infiltrate. At the same time, absolute CD4 + lymphocyte was 38/l. Eight months after the completion of fludarabine, the absolute CD4
+ lymphocyte was 173/l without complication and remained stable at 166/l 17 months after the end of fludarabine regimen. Twenty-two months after first line of fludarabine, recurrence occurred with an increase of IgM level to 35 g/l and adenopathy involvement.
His absolute CD4
+ and CD8 + lymphocyte counts were 245/l and 395/l, respectively. A second line of fludarabine began at the 25 mg/m 2 /day × 5 days every month. Six cycles were done without complication and induced a PR. At the completion of the treatment, the absolute lymphocyte count was 720/l with 172/l CD4 + and 200/l CD8 + . The patient remained in PR 8 months later without any infectious complication.
The purine nucleoside analogs 2-CdA and fludarabine have shown significant activity in low-grade lymphoid malignancies, including hairy cell leukemia, chronic lymphocytic leukemia, and indolent lymphoma. 5 Preliminary non-randomized studies showed that fludarabine has a substantial role in the management of WM. 6, 7 Efficacy of fludarabine in WM has been confirmed recently in a multicentric randomized study comparing fludarabine with CAP regimen in a patient in first relapse or primary refractory disease. In this study, the response rate to fludarabine was 28% compared to 11% in the CAP arm. Moreover, the time to progression and time to treatment failure were significantly longer in the fludarabine arm. 8 Although the short-term toxicities are generally limited to those associated with the period of myelosuppression following therapy, the drug induces profound and prolonged suppression of normal CD4 + and CD8
+ lymphocyte counts. 9 Significant adverse effects such as an increased incidence of opportunistic infections or secondary malignancies have nevertheless not been observed. 9 However, major complications such as respiratory tract infections or Listeria monocyto- genes septicemia, and herpes zoster were reported from a previous study. 8 In the present data, no infection was noted despite a profound lymphopenia and a CD4 + level less than 200/l over a 36-month period.
The purine analogs offer innovative therapy in the treatment of WM, which can be resistant to alkylating agents and steroids. Our data suggest that a patient with previous response to fludarabine could experience a similar response at the fludarabine reinduction. Comparable results were reported with 2CdA and 2Ј-deoxycoformycin in hairy cell leukemia. 10 Moreover, no worsening of immunosuppression was observed. However, our observation was limited to a single case and further large-scale studies are needed to confirm our findings.
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